US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

GRACE THERAPEUTICS INC

3.02

+0.06002.03%

Volume:50.36K

Turnover:151.44K

Market Cap:41.76M

PE:-3.82

High:3.03

Open:2.98

Low:2.98

Close:2.96

Loading ...

Overview Company News Filings

Grace Therapeutics Inc. Unveils Presentation on Groundbreaking GTx-104 Therapy for aSAH

BRIEF-Grace Therapeutics Announces Submission Of New Drug Application To US FDA For Gtx-104

Grace Therapeutics- Nda Submission Includes Positive Data From Phase 3 Strive-on Trial

THOMSON REUTERS

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for Gtx-104

THOMSON REUTERS

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

THOMSON REUTERS

Press Release: Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Grace Therapeutics Inc. Reports Increased Net Loss of $16.7 Million for Fiscal Year Ending March 31, 2025, Compared to $12.9 Million Loss in Previous Year

Calendar of U.S. Earnings Expected in the Week Ahead

Calendar of U.S. Earnings Expected in the Week Ahead

TD Cowen Initiates Coverage on Grace Therapeutics With Buy Rating, $12 Price Target

MT Newswires Live

BRIEF-Grace Therapeutics Announces Alignment With The FDA Supporting The Submission For Gtx-104

Grace Therapeutics, Inc: Anticipates Filing Its Nda for Gtx-104 in Q2 of 2025

THOMSON REUTERS

Grace Therapeutics Announces Alignment With the FDA Supporting the Planned Nda Submission for Gtx-104

THOMSON REUTERS

BRIEF-Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing shows

Grace Therapeutics, Inc Files for Shelf of up to up to 8.8 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS

GRCE: STRIVE-ON Results Reported

Zacks Small Cap Research

Grace Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Grace Therapeutics, Inc - Q3 Shr Loss $0.36

THOMSON REUTERS

Grace Therapeutics Q3 EPS $(0.36) Vs $(0.34) Estimate

Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GRCE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRCE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRCE\",,,,,undefined,":{"symbol":"GRCE","market":"US","secType":"STK","nameCN":"GRACE THERAPEUTICS INC","latestPrice":3.02,"timestamp":1751486400000,"preClose":2.96,"halted":0,"volume":50362,"delay":0,"floatShares":7714224,"shares":13828562,"eps":-0.791576,"marketStatus":"Pre-Mkt","change":0.06,"latestTime":"07-03 08:45:07 EDT","open":2.978868,"high":3.03,"low":2.978868,"amount":151438.6750136,"amplitude":0.017274,"askPrice":3.29,"askSize":100,"bidPrice":2.94,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-0.791576,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751549400000},"marketStatusCode":1,"adr":0,"listingDate":1357534800000,"exchange":"NASDAQ","adjPreClose":3.02,"postHourTrading":{"tag":"盘后","latestPrice":3.02,"preClose":3.02,"latestTime":"17:25 EDT","volume":104,"amount":315.4,"timestamp":1751491542521},"volumeRatio":1.3994342405976776},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRCE\",,,,,undefined,":{"symbol":"GRCE","floatShares":7714224,"roa":"-14.35%","roe":"-14.91%","lyrEps":-0.791576,"volumeRatio":1.3994342405976776,"shares":13828562,"dividePrice":0,"high":3.03,"amplitude":0.017274,"preClose":2.96,"low":2.978868,"week52Low":1.75,"pbRate":"0.63","week52High":4.965,"institutionHeld":0,"latestPrice":3.02,"committee":-0.960784,"eps":-0.791576,"divideRate":0,"volume":50362,"delay":0,"ttmEps":-0.791576,"open":2.978868,"prevYearClose":3.74,"prevWeekClose":2.97,"prevMonthClose":2.97,"prevQuarterClose":2.97,"fiveDayClose":2.96,"twentyDayClose":2.82,"sixtyDayClose":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRCE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546844248","title":"Grace Therapeutics Inc. Unveils Presentation on Groundbreaking GTx-104 Therapy for aSAH","url":"https://stock-news.laohu8.com/highlight/detail?id=2546844248","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546844248?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:46","pubTimestamp":1750855567,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. has shared a corporate presentation detailing their recent advancements and initiatives. The presentation highlights GTx-104, a novel intravenous formulation of nimodipine, developed to address the challenges associated with the current standard of care, which is available only in oral form. This new therapy has shown promising results in a pivotal Phase 3 STRIVE-ON safety trial, achieving its primary endpoint and demonstrating clinical benefits over the oral version. The presentation also mentions the submission of a New Drug Application  in June 2025, alongside the potential of GTx-104 to address severe rare diseases under Orphan Drug Status, granting it seven-year market exclusivity and multi-layered intellectual property protection. The context provided emphasizes the significant unmet needs in treating aneurysmal Subarachnoid Hemorrhage , a condition with high mortality rates that affects relatively young patients. You can access the full presentation throu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL8pd7kg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2546210884","title":"BRIEF-Grace Therapeutics Announces Submission Of New Drug Application To US FDA For Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2546210884","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546210884?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:23","pubTimestamp":1750854198,"startTime":"0","endTime":"0","summary":"BRIEF-Grace Therapeutics Announces Submission Of New Drug Application To US FDA For Gtx-104June 25 (Reuters) - Grace Therapeutics, Inc GRCE.O:GRACE THERAPEUTICS ANNOUNCES SUBMISSION OF NEW DRUG APPLIC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA14PQSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2546217991","title":"Grace Therapeutics- Nda Submission  Includes Positive Data From Phase 3 Strive-on Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2546217991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546217991?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:00","pubTimestamp":1750852800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA14PQSN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2546120712","title":"Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2546120712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546120712?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:00","pubTimestamp":1750852800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA14PQSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2545419488","title":"Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419488?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:00","pubTimestamp":1750680002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA4VNYGZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2545419213","title":"Press Release: Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419213","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419213?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:00","pubTimestamp":1750680000,"startTime":"0","endTime":"0","summary":"Held Type C meeting with FDA on Planned New Drug Application  Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control  Requirements. NDA On Track for Submission to FDA in First Half of Calendar 2025. \"Our focus now is to finalize our NDA submission for GTx-104, which we expect to complete by the end of June 2025. The standard of care for aSAH has not seen meaningful innovation in nearly 40 years. Data from our STRIVE-ON trial exceeded our expectations, and although STRIVE-ON was not designed or powered to demonstrate efficacy, the data provide support for improved clinical outcomes for patients treated with GTx-104 when compared to patients treated with orally administered nimodipine. Importantly, the data also provides both medical and pharmacoeconomic evidence of the potential benefit of GTx-104 in aSAH patients, which could help drive adoption of GTx-104 by neurocritical care physicians and hospital pharmacies. We believe the STRIVE-ON trial results p","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861214812.USD","LU0971096721.USD","BK4512","IE00BHPRN162.USD","LU2357305700.SGD","LU1548497426.USD","BK4588","LU1363072403.SGD","LU0348723411.USD","LU1720051017.SGD","BK4082","LU1978683503.SGD","CMC","LU1861219969.SGD","LU0170899867.USD","LU0724618433.USD","LU2360107325.USD","LU2298322129.HKD","IE00BZ1G4Q59.USD","BK4585","LENZ","RDI","LU1720051108.HKD","BK4141","LU0124384867.USD","BK4007","GRCE","IE00B1BXHZ80.USD","IE00BKVL7J92.USD","ICU","LU0882574139.USD","LU1861215975.USD","LU1854103824.USD","BK4605","BK4108","LU1854104046.USD","LU1861220033.SGD","LU0267386448.USD","BK4539","BK4139","LU0149725797.USD","BK4006","IE00BZ199S13.USD","ON","IE00BD6J9T35.USD"],"gpt_icon":0},{"id":"2545419301","title":"Grace Therapeutics Inc. Reports Increased Net Loss of $16.7 Million for Fiscal Year Ending March 31, 2025, Compared to $12.9 Million Loss in Previous Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2545419301","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545419301?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:45","pubTimestamp":1750679104,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Inc. Reports Increased Net Loss of $16.7 Million for Fiscal Year Ending March 31, 2025, Compared to $12.9 Million Loss in Previous Year. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL2ZFfJ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Grace Therapeutics Inc. Reports Increased Net Loss of $16.7 Million for Fiscal Year Ending March 31, 2025, Compared to $12.9 Million Loss in Previous Year","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2545418643","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2545418643","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545418643?lang=en_us&edition=fundamental","pubTime":"2025-06-23 18:00","pubTimestamp":1750672800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Carnival plc Sp ADR                              2Q       .24   9:15 AM. ·TD SYNNEX Corp                                   2Q      2.72   8:05 AM. ·General Mills Inc.                               4Q       .71   7:00 AM. ·McCormick & Co                                 2Q       .65   6:30 AM. ·NIKE Inc. Class B                                4Q       .12   4:15 PM. ·Walgreens Boots Allnc                            3Q       .33   7:00 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KBH","BK4089","MKC.V","BK4128","CUK","BK4603","BK4568","BK4532","JEF","MU","AYI","DAKT","MLKN","BK4581","CMC","PAYX","LU1585245621.USD","AMC","FDS","RDUS","WOR","LU2404859741.USD","ATEX","HIVE","LU2095319765.USD","LU2065170008.USD","NKE","LU0203345920.USD","WGO","AEMD","BK4527","SNX","BK4187","LNN","BK4597","GP","WBA","APOG","FDX","GRCE","LU1989763690.USD","SCS","OESX","GIS","AVAV","FUL","CNXC","LU2048586759.USD","MKC"],"gpt_icon":1},{"id":"2544123059","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2544123059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544123059?lang=en_us&edition=fundamental","pubTime":"2025-06-20 18:00","pubTimestamp":1750413600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Accenture Plc Class A                            3Q      3.32   6:39 AM. ·TD SYNNEX Corp                                   2Q      2.72   8:05 AM. ·General Mills Inc.                               4Q       .71   7:00 AM. ·McCormick & Co                                 2Q       .65   6:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXC","PENG","WOR","LU0648001328.SGD","FUL","KBH","FDX","AVAV","MKC.V","LU0868494617.USD","OESX","NKE","WBA","AEMD","LU0267386448.USD","AMC","LU0130517989.USD","GIS","LU2095319765.USD","KR","WGO","BK4146","DAKT","RDUS","MLKN","DRI","ATEX","LU0274383776.USD","MKC","PAYX","SG9999017495.SGD","GRCE","BK4123","JEF","SNX","FC","LNN","LU0056508442.USD","FDS","KMX","AYI","HIVE","IE00BVYPNW00.USD","SCS","MU","ACN","CUK","CMC","LU1003077747.HKD"],"gpt_icon":1},{"id":"2532720817","title":"TD Cowen Initiates Coverage on Grace Therapeutics With Buy Rating, $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2532720817","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532720817?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:30","pubTimestamp":1746185430,"startTime":"0","endTime":"0","summary":"Grace Therapeutics, Inc. (GRCE) has an average rating of Buy and mean price target of $11.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRCE","LENZ","TD","COWN"],"gpt_icon":0},{"id":"2526736317","title":"BRIEF-Grace Therapeutics Announces Alignment With The FDA Supporting The Submission For Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2526736317","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526736317?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:13","pubTimestamp":1744200815,"startTime":"0","endTime":"0","summary":"BRIEF-Grace Therapeutics Announces Alignment With The FDA Supporting The Submission For Gtx-104April 9 (Reuters) - Grace Therapeutics, Inc GRCE.O:GRACE THERAPEUTICS ANNOUNCES ALIGNMENT WITH THE FDA SU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN07P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2526368293","title":"Grace Therapeutics, Inc: Anticipates Filing Its Nda for Gtx-104 in Q2 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526368293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526368293?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:00","pubTimestamp":1744200019,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN07P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2526368257","title":"Grace Therapeutics Announces Alignment With the FDA Supporting the Planned Nda Submission for Gtx-104","url":"https://stock-news.laohu8.com/highlight/detail?id=2526368257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526368257?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:00","pubTimestamp":1744200019,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN07P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2518221085","title":"BRIEF-Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2518221085","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518221085?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:26","pubTimestamp":1741613193,"startTime":"0","endTime":"0","summary":"BRIEF-Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing showsMarch 10 (Reuters) - Grace Therapeutics, Inc GRCE.O:GRACE THERAPEUTICS, INC FILES FOR SHELF OF UP TO UP ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"gpt_icon":0},{"id":"2518228383","title":"Grace Therapeutics, Inc Files for Shelf of up to up to 8.8 Mln Shares of Common Stock by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228383","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518228383?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:59","pubTimestamp":1741607955,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT0MG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2513963232","title":"GRCE: STRIVE-ON Results Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2513963232","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513963232?lang=en_us&edition=fundamental","pubTime":"2025-02-21 17:40","pubTimestamp":1740130800,"startTime":"0","endTime":"0","summary":"Grace Therapeutics, Inc  reported fiscal year  third quarter results following a series of announcements regarding conference participation, the raise of additional capital and results from the Phase III STRIVE-ON trial for GTx-104. The most important information was the data from the Phase III safety trial. In patients, it found excellent relative dose intensity, better outcomes, fewer intensive care unit readmissions and fewer ventilator days for GTx-104 compared with oral nimodipine. Following the data release, Grace executed a capital raise to fund pre-commercial development of GTx-104.Grace reported third quarter fiscal year 2025 results in a press release and Form 10-Q filing with the SEC on February 13th. For the quarter ending December 31, 2024, operating expenses of $3.7 million were recognized. Net loss for 3Q:25 totaled  million or  per share. For FY 3Q:25 versus the same prior year period:. General & Administrative expenses were $1.5 million, down 4% from $1.6 million attri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grce-strive-results-reported-094000032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4141","LU1720051108.HKD","LU1861220033.SGD","LU0124384867.USD","LU2360107325.USD","BK4082","LU1854103824.USD","LU1861219969.SGD","LU0724618433.USD","LU1861214812.USD","BK4512","IE00BD6J9T35.USD","LU1978683503.SGD","LU2298322129.HKD","ICU","BK4605","LU0348723411.USD","LU1720051017.SGD","ON","LU1861215975.USD","GRCE","LU2357305700.SGD","BK4588","BK4585","IE00BZ199S13.USD","BK4108","RDI","LU1854104046.USD","LU1548497426.USD","BK4007"],"gpt_icon":0},{"id":"2512156579","title":"Grace Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2512156579","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512156579?lang=en_us&edition=fundamental","pubTime":"2025-02-18 19:47","pubTimestamp":1739879220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GRCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 06:47 ET (11:47 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","GRCE"],"gpt_icon":0},{"id":"2511017542","title":"Grace Therapeutics, Inc - Q3 Shr Loss $0.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2511017542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511017542?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:13","pubTimestamp":1739452424,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P41XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"gpt_icon":0},{"id":"2511424875","title":"Grace Therapeutics Q3 EPS $(0.36) Vs $(0.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2511424875","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511424875?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:07","pubTimestamp":1739452029,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Q3 EPS $(0.36) Vs $(0.34) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43691440/grace-therapeutics-q3-eps-0-36-vs-0-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","LENZ"],"gpt_icon":0},{"id":"2510497896","title":"Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2510497896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510497896?lang=en_us&edition=fundamental","pubTime":"2025-02-11 02:44","pubTimestamp":1739213048,"startTime":"0","endTime":"0","summary":"Grace Therapeutics  rose nearly 8% in recent Monday trading after it said it entered into securities purchase agreements for a private placement financing of up to $30 million with healthcare-focused institutional investors.The financing consists of an initial upfront funding of about $15 million, with an additional potential $15 million if accompanying warrants are exercised for cash. The deal is expected to close on Tuesday, subject to customary closing conditions.As part of the financing, Grace Therapeutics will issue about 4.4 million common shares, or pre-funded warrants in lieu thereof, along with warrants to purchase up to an additional 4.4 million shares at a combined purchase price of $3.395 per share.Each warrant allows the holder to purchase one share at $3.395 and will expire either 60 days after the US Food and Drug Administration approves the New Drug Application for GTx-104 or on Sept. 25, 2028.If all warrants are exercised, Grace Therapeutics could receive up to $15 mil","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GRCE","LENZ","BK4007","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRCE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-23","symbol":"GRCE","fiscalQuarterEnding":"2025/03","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1750651200000,"reportTimeType":"pre","actualEps":-0.21},{"market":"US","date":"2025-02-13","symbol":"GRCE","fiscalQuarterEnding":"2024/12","expectedEps":-0.24,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1739422800000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2024-11-13","symbol":"GRCE","fiscalQuarterEnding":"2024/09","expectedEps":-0.33,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.33},{"market":"US","date":"2024-08-09","symbol":"GRCE","fiscalQuarterEnding":"2024/06","expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"pre","actualEps":-0.24},{"market":"US","date":"2024-06-21","symbol":"GRCE","fiscalQuarterEnding":"2024/03","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1718942400000,"reportTimeType":"pre","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRCE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRCE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1746244800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRCE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRCE","date":"2025-07-01","current":-4.29252,"percent":0.006098,"low":-4.335879,"twenty":-3.234341,"median":-2.883124,"eighty":-2.328942,"high":-1.653321,"avg":-2.837918,"sd":0.560001,"marketCap":41070829},"quantilePoints":[{"date":"2024-10-31","current":-2.746009,"twenty":-2.84522,"median":-2.808016,"eighty":-2.770812,"marketCap":31433569},{"date":"2024-11-08","current":-2.737151,"twenty":-2.770812,"median":-2.746009,"eighty":-2.701719,"marketCap":31332170},{"date":"2024-11-15","current":-2.891861,"twenty":-2.815988,"median":-2.74158,"eighty":-2.694633,"marketCap":33562939},{"date":"2024-11-22","current":-2.821967,"twenty":-2.824979,"median":-2.746009,"eighty":-2.701719,"marketCap":32751751},{"date":"2024-11-29","current":-2.935545,"twenty":-2.870023,"median":-2.76081,"eighty":-2.701719,"marketCap":34069932},{"date":"2024-12-06","current":-3.791745,"twenty":-2.935545,"median":-2.823849,"eighty":-2.717126,"marketCap":44006996},{"date":"2024-12-13","current":-3.407329,"twenty":-3.407329,"median":-2.865651,"eighty":-2.737151,"marketCap":39545457},{"date":"2024-12-20","current":-3.547117,"twenty":-3.407329,"median":-2.887493,"eighty":-2.746009,"marketCap":41167835},{"date":"2024-12-27","current":-3.232594,"twenty":-3.39335,"median":-2.931176,"eighty":-2.746009,"marketCap":37517485},{"date":"2025-01-03","current":-3.494696,"twenty":-3.396845,"median":-2.953018,"eighty":-2.749647,"marketCap":40559444},{"date":"2025-01-10","current":-3.582064,"twenty":-3.494696,"median":-3.066596,"eighty":-2.755568,"marketCap":41573430},{"date":"2025-01-17","current":-2.935545,"twenty":-3.494696,"median":-3.057859,"eighty":-2.767291,"marketCap":34069932},{"date":"2025-01-24","current":-3.437907,"twenty":-3.492949,"median":-3.145227,"eighty":-2.786004,"marketCap":39900353},{"date":"2025-01-31","current":-2.778283,"twenty":-3.476349,"median":-3.13649,"eighty":-2.78702,"marketCap":32244757},{"date":"2025-02-07","current":-2.918071,"twenty":-3.433539,"median":-3.040386,"eighty":-2.785272,"marketCap":33867135},{"date":"2025-02-14","current":-3.040386,"twenty":-3.416065,"median":-3.038201,"eighty":-2.814977,"marketCap":35286716},{"date":"2025-02-21","current":-2.570989,"twenty":-3.416065,"median":-3.009807,"eighty":-2.777013,"marketCap":34374128},{"date":"2025-02-28","current":-2.29038,"twenty":-3.407329,"median":-2.996702,"eighty":-2.746009,"marketCap":30622380},{"date":"2025-03-07","current":-2.050724,"twenty":-3.407329,"median":-2.952538,"eighty":-2.701719,"marketCap":27418184},{"date":"2025-03-14","current":-1.736745,"twenty":-3.389855,"median":-2.935545,"eighty":-2.613138,"marketCap":23220281},{"date":"2025-03-21","current":-1.941514,"twenty":-3.363645,"median":-2.904966,"eighty":-2.495149,"marketCap":25958044},{"date":"2025-03-28","current":-2.329102,"twenty":-3.337435,"median":-2.883124,"eighty":-2.329102,"marketCap":31140100},{"date":"2025-04-04","current":-2.25728,"twenty":-3.328698,"median":-2.865651,"eighty":-2.3283,"marketCap":30179833},{"date":"2025-04-11","current":-1.99051,"twenty":-3.319961,"median":-2.825732,"eighty":-2.29038,"marketCap":26613125},{"date":"2025-04-17","current":-2.093114,"twenty":-3.278025,"median":-2.81323,"eighty":-2.187348,"marketCap":27984936},{"date":"2025-04-25","current":-2.441966,"twenty":-3.253562,"median":-2.777648,"eighty":-2.187348,"marketCap":32649092},{"date":"2025-05-02","current":-2.780558,"twenty":-3.243078,"median":-2.76081,"eighty":-2.203926,"marketCap":37176067},{"date":"2025-05-09","current":-2.872902,"twenty":-3.234341,"median":-2.778283,"eighty":-2.214186,"marketCap":38410696},{"date":"2025-05-16","current":-2.784047,"twenty":-3.204636,"median":-2.778283,"eighty":-2.249072,"marketCap":37222708},{"date":"2025-05-23","current":-3.04702,"twenty":-3.183669,"median":-2.787433,"eighty":-2.28376,"marketCap":40738659},{"date":"2025-05-30","current":-2.978583,"twenty":-3.159206,"median":-2.802024,"eighty":-2.29493,"marketCap":39823661},{"date":"2025-06-06","current":-3.037068,"twenty":-3.145227,"median":-2.825732,"eighty":-2.310491,"marketCap":40605593},{"date":"2025-06-13","current":-2.996026,"twenty":-3.145227,"median":-2.855425,"eighty":-2.319966,"marketCap":40056869},{"date":"2025-06-20","current":-3.149932,"twenty":-3.145227,"median":-2.867837,"eighty":-2.32375,"marketCap":42114585},{"date":"2025-06-27","current":-4.249161,"twenty":-3.190658,"median":-2.872902,"eighty":-2.328621,"marketCap":40655972},{"date":"2025-07-01","current":-4.29252,"twenty":-3.234341,"median":-2.883124,"eighty":-2.328942,"marketCap":41070829}],"updateTime":1751521774638}}}